

Jens Bedke

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8511426/publications.pdf>

Version: 2024-02-01

250
papers

14,763
citations

76196

40
h-index

22102

113
g-index

285
all docs

285
docs citations

285
times ranked

12581
citing authors

#	ARTICLE	IF	CITATIONS
1	Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial. <i>European Urology Oncology</i> , 2022, 5, 225-234.	2.6	17
2	Robotic Transrectal Computed Tomographic Ultrasound with Artificial Neural Network Analysis: First Validation and Comparison with MRI-Guided Biopsies and Radical Prostatectomy. <i>Urologia Internationalis</i> , 2022, 106, 90-96.	0.6	3
3	On the probability of lymph node negativity in pNO-staged prostate cancer—a theoretically derived rule of thumb for adjuvant needs. <i>Strahlentherapie Und Onkologie</i> , 2022, 198, 690-699.	1.0	1
4	Diagnostic benefit of multiparametric MRI over contrast-enhanced CT in patients with bladder cancer: A single-center 1-year experience. <i>European Journal of Radiology</i> , 2022, 146, 110059.	1.2	2
5	Thioredoxin 1 (Trx1) is associated with poor prognosis in clear cell renal cell carcinoma (ccRCC): an example for the crucial role of redox signaling in ccRCC. <i>World Journal of Urology</i> , 2022, 40, 739-746.	1.2	5
6	Is a single portal venous phase in contrast-enhanced CT sufficient to detect metastases or recurrence in clear cell renal cell carcinoma? — a single-center retrospective study. <i>Cancer Imaging</i> , 2022, 22, 9.	1.2	1
7	2021 Updated European Association of Urology Guidelines on the Use of Adjuvant Pembrolizumab for Renal Cell Carcinoma. <i>European Urology</i> , 2022, 81, 134-137.	0.9	29
8	Prognostic impact of complete metastasectomy in metastatic renal cell carcinoma in the era of immuno-oncology-based combination therapies. <i>World Journal of Urology</i> , 2022, 40, 1175-1183.	1.2	5
9	Variation across operating sites in urinary and sexual outcomes after radical prostatectomy in localized and locally advanced prostate cancer. <i>World Journal of Urology</i> , 2022, 40, 1437-1446.	1.2	7
10	T2 mapping for the characterization of prostate lesions. <i>World Journal of Urology</i> , 2022, 40, 1455-1461.	1.2	4
11	European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. <i>European Urology</i> , 2022, 82, 399-410.	0.9	485
12	Real-World Data on the Use of Nivolumab Monotherapy in the Treatment of Advanced Renal Cell Carcinoma after Prior Therapy: Interim Results from the Noninterventional NORA Study. <i>European Urology Focus</i> , 2022, 8, 1289-1299.	1.6	4
13	Role of the Systemic Immune-Inflammation Index in Patients with Metastatic Renal Cell Carcinoma Treated with First-Line Ipilimumab plus Nivolumab. <i>Cancers</i> , 2022, 14, 2972.	1.7	13
14	Nicotinamide adenine dinucleotide-dependent methyltransferase is a promising metabolic drug target for primary and metastatic clear cell renal cell carcinoma. <i>Clinical and Translational Medicine</i> , 2022, 12, .	1.7	20
15	Reply to Yongbao Wei, Ruochen Zhang, and Le Lin's Letter to the Editor re: Börje Ljungberg, Laurence Albiges, Yasmin Abu-Ghanem, et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. <i>Eur Urol</i> . 2022;82:e88. <i>European Urology</i> , 2022, 82, e111-e112.	0.9	7
16	Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma. <i>European Urology</i> , 2022, 82, 427-439.	0.9	15
17	Partial Response and Stable Disease Correlate with Positive Outcomes in Atezolizumab-treated Patients with Advanced Urinary Tract Carcinoma. <i>European Urology Focus</i> , 2021, 7, 1084-1091.	1.6	4
18	Enfortumab vedotin — next game-changer in urothelial cancer. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 801-809.	1.4	17

#	ARTICLE	IF	CITATIONS
19	Genetic analysis of primary renal cell carcinoma to determine treatment approaches. Expert Review of Precision Medicine and Drug Development, 2021, 6, 107-115.	0.4	1
20	Outcomes for patients in the pembrolizumab+axitinib arm with advanced renal cell carcinoma (RCC) who completed two years of treatment in the phase III KEYNOTE-426 study.. Journal of Clinical Oncology, 2021, 39, 327-327.	0.8	8
21	The prognostic value of fat invasion and tumor expansion in the hilar veins in pT3a renal cell carcinoma. World Journal of Urology, 2021, 39, 3367-3376.	1.2	6
22	Combination of immune checkpoint inhibitors and tyrosine kinase inhibitors for the treatment of renal cell carcinoma. Expert Opinion on Biological Therapy, 2021, 21, 1215-1226.	1.4	10
23	Nivolumab + cabozantinib (NIVO+CABO) versus sunitinib (SUN) for advanced renal cell carcinoma (aRCC): Outcomes by sarcomatoid histology and updated trial results with extended follow-up of CheckMate 9ER.. Journal of Clinical Oncology, 2021, 39, 308-308.	0.8	48
24	Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 2021, 384, 829-841.	13.9	961
25	Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma. European Urology, 2021, 79, 339-342.	0.9	98
26	Dual immune check point blockade or immune check point-tyrosine kinase inhibitor combination: as a first-line treatment in metastatic renal cell carcinoma?. Current Opinion in Urology, 2021, 31, 270-275.	0.9	5
27	Expression patterns of the immune checkpoint ligand CD276 in urothelial carcinoma. BMC Urology, 2021, 21, 60.	0.6	10
28	Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. New England Journal of Medicine, 2021, 384, 1289-1300.	13.9	956
29	Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology, The, 2021, 22, 525-537.	5.1	225
30	Editorial: Standard and future in the treatment of renal cell carcinoma. Current Opinion in Urology, 2021, 31, 226-227.	0.9	0
31	Outcomes of EAU-endorsed Live Surgical Events over a 5-year Period (2015â€“2020) and Updated Guidelines from the EAU Live Surgery Committee. European Urology, 2021, 80, 592-600.	0.9	4
32	Pembrolizumab for the treatment of renal cell carcinoma. Expert Opinion on Biological Therapy, 2021, 21, 1157-1164.	1.4	2
33	Re: Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. European Urology, 2021, 80, 257-258.	0.9	2
34	Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: Phase III KEYNOTE-866 and KEYNOTE-905/EV-303. Future Oncology, 2021, 17, 3137-3150.	1.1	21
35	Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. New England Journal of Medicine, 2021, 385, 683-694.	13.9	394
36	p53 is functionally inhibited in clear cell renal cell carcinoma (ccRCC): a mechanistic and correlative investigation into genetic and molecular characteristics. Journal of Cancer Research and Clinical Oncology, 2021, 147, 3565-3576.	1.2	5

#	ARTICLE	IF	CITATIONS
37	The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naïve Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care. <i>European Urology</i> , 2021, 80, 393-397.	0.9	103
38	Characterization of Genetic Heterogeneity in Recurrent Metastases of Renal Cell Carcinoma. <i>Cancers</i> , 2021, 13, 6221.	1.7	1
39	⁶⁸ Ga-PSMA-PET/CT-directed IGRT/SBRT for oligometastases of recurrent prostate cancer after initial surgery. <i>Acta Oncologica</i> , 2020, 59, 149-156.	0.8	9
40	Immune checkpoint inhibition for the treatment of renal cell carcinoma. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 83-94.	1.4	14
41	Simultaneous whole-body PET/MRI with integrated multiparametric MRI for primary staging of high-risk prostate cancer. <i>World Journal of Urology</i> , 2020, 38, 2513-2521.	1.2	17
42	Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 105-120.	5.1	61
43	Hypertonicity-Affected Genes Are Differentially Expressed in Clear Cell Renal Cell Carcinoma and Correlate with Cancer-Specific Survival. <i>Cancers</i> , 2020, 12, 6.	1.7	13
44	Optimized protocol for metabolomic and lipidomic profiling in formalin-fixed paraffin-embedded kidney tissue by LC-MS. <i>Analytica Chimica Acta</i> , 2020, 1134, 125-135.	2.6	15
45	Consensus paper: current state of first- and second-line therapy in advanced clear-cell renal cell carcinoma. <i>Future Oncology</i> , 2020, 16, 2307-2328.	1.1	17
46	Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1563-1573.	5.1	466
47	Retroperitoneal Fibrosis and its Differential Diagnoses: The Role of Radiological Imaging. <i>RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren</i> , 2020, 192, 929-936.	0.7	12
48	Systemic treatment of advanced/metastatic renal cell carcinoma in the context of SARS-CoV-2 pandemic: recommendations from the interdisciplinary working group for renal tumors (IAG-N). <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 3075-3078.	1.2	4
49	An evaluation of avelumab for the treatment of genitourinary tumors. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 971-979.	1.4	4
50	Enzalutamide plus androgen-deprivation therapy in hormone-sensitive prostate cancer: new perspectives from a current Phase III clinical trial. <i>Future Oncology</i> , 2020, 16, 1511-1523.	1.1	1
51	Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy. <i>Genome Medicine</i> , 2020, 12, 32.	3.6	32
52	Age-Adapted Prostate Cancer Gene 3 Score Interpretation - Suggestions for Clinical Use. <i>Clinical Laboratory</i> , 2020, 66, .	0.2	3
53	Analysis of clinical outcomes according to response status in prospective clinical trials of atezolizumab (atezo) in pretreated locally advanced/metastatic urothelial carcinoma (mUC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 492-492.	0.8	0
54	Emphysematous Cystitis. <i>Deutsches A&#x0308;rztblatt International</i> , 2020, 117, .	0.6	4

#	ARTICLE	IF	CITATIONS
55	Transurethral Resection of Bladder Tumors: Next-generation Virtual Reality Training for Surgeons. <i>European Urology Focus</i> , 2019, 5, 906-911.	1.6	29
56	PD-1 and LAG-3 Dominate Checkpoint Receptor-Mediated T-cell Inhibition in Renal Cell Carcinoma. <i>Cancer Immunology Research</i> , 2019, 7, 1891-1899.	1.6	66
57	SIU-ICUD consultation on bladder cancer: treatment of muscle-invasive bladder cancer. <i>World Journal of Urology</i> , 2019, 37, 61-83.	1.2	40
58	Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. <i>Lancet</i> , The, 2019, 393, 2404-2415.	6.3	778
59	Circulating tumor cells and their role in prostate cancer. <i>Asian Journal of Andrology</i> , 2019, 21, 24.	0.8	13
60	Assessment of concomitant non-oncologic medication in patients with surgically treated renal cell carcinoma: impact on prognosis, cell-cycle progression and proliferation. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1835-1843.	1.2	12
61	Intention-to-Treat Analysis of ⁶⁸ Ga-PSMA and ¹¹ C-Choline PET/CT Versus CT for Prostate Cancer Recurrence After Surgery. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1359-1365.	2.8	29
62	Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2019, 380, 1103-1115.	13.9	1,824
63	Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2019, 380, 1116-1127.	13.9	2,319
64	Active Smoking Is Associated With Worse Prognosis in Metastatic Renal Cell Carcinoma Patients Treated With Targeted Therapies. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 65-71.	0.9	9
65	SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11). <i>European Journal of Cancer</i> , 2019, 107, 37-45.	1.3	21
66	mTOR and mTOR phosphorylation status in primary and metastatic renal cell carcinoma tissue: differential expression and clinical relevance. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 153-163.	1.2	16
67	Molecular predictors of response to PD-1/PD-L1 inhibition in urothelial cancer. <i>World Journal of Urology</i> , 2019, 37, 1773-1784.	1.2	22
68	Can contrast-enhanced ultrasound and acoustic radiation force impulse imaging characterize CT-indeterminate renal masses? A prospective evaluation with histological confirmation. <i>World Journal of Urology</i> , 2019, 37, 1339-1346.	1.2	15
69	Role of multiparametric magnetic resonance imaging for patients under active surveillance for prostate cancer: a systematic review with diagnostic meta-analysis. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 206-220.	2.0	19
70	Can urinary biomarkers replace cystoscopy?. <i>World Journal of Urology</i> , 2019, 37, 1741-1749.	1.2	37
71	Results of a Phase 1/2 Study in Metastatic Renal Cell Carcinoma Patients Treated with a Patient-specific Adjuvant Multi-peptide Vaccine after Resection of Metastases. <i>European Urology Focus</i> , 2019, 5, 604-607.	1.6	17
72	Metabolic and Lipidomic Reprogramming in Renal Cell Carcinoma Subtypes Reflects Regions of Tumor Origin. <i>European Urology Focus</i> , 2019, 5, 608-618.	1.6	35

#	ARTICLE	IF	CITATIONS
73	Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study.. Journal of Clinical Oncology, 2019, 37, 4500-4500.	0.8	85
74	Atezolizumab (atezo) + bevacizumab (bev) versus sunitinib (sun) in pts with untreated metastatic renal cell carcinoma (mRCC) and sarcomatoid (sarc) histology: IMmotion151 subgroup analysis.. Journal of Clinical Oncology, 2019, 37, 4512-4512.	0.8	30
75	Nivolumab monotherapy in patients with advanced platinum-resistant urothelial carcinoma: Efficacy and safety update from CheckMate 275.. Journal of Clinical Oncology, 2019, 37, 4524-4524.	0.8	11
76	Sequential treatment with pazopanib (PAZO) followed by nivolumab (NIVO) in patients with advanced or metastatic renal cell carcinoma (mRCC): Third interim results of the non-interventional study PAZOREAL.. Journal of Clinical Oncology, 2019, 37, 4574-4574.	0.8	2
77	Current concepts and trends in the treatment of bone metastases in patients with advanced prostate cancer. Asian Journal of Andrology, 2019, 21, 12.	0.8	5
78	Determination of Free-PSA (fPSA) and fPSA/PSA-Ratio Using A Point-of-Care Device. Clinical Laboratory, 2019, 65, .	0.2	1
79	Impact of 68Ga-PSMA PET/CT on treatment in patients with recurrent prostate cancer: comparison with 11C-choline PET and diagnostic CT. , 2019, 58, .		0
80	A prospective, open label, multicenter, randomized phase II trial: Sequential therapy with bevacizumab, RAd001 (everolimus) and axitinib in metastatic renal cell carcinoma (mRCC) (BERAT study).. Journal of Clinical Oncology, 2019, 37, e16097-e16097.	0.8	0
81	Abstract 2529: Comprehensive genomic analyses of a case series of bilateral renal cell carcinoma. , 2019, , .		0
82	No influence of smoking status on the performance of urine markers for the detection of bladder cancer. Journal of Cancer Research and Clinical Oncology, 2018, 144, 1367-1373.	1.2	8
83	Cognitive versus Software-Assisted Registration: Development of a New Nomogram Predicting Prostate Cancer at MRI-Targeted Biopsies. Clinical Genitourinary Cancer, 2018, 16, e953-e960.	0.9	9
84	Rare and changeable as a chameleon: paraneoplastic syndromes in renal cell carcinoma. World Journal of Urology, 2018, 36, 849-854.	1.2	22
85	Prostate cancer detection in patients with prior negative biopsy undergoing cognitive-, robotic- or in-bore MRI target biopsy. World Journal of Urology, 2018, 36, 761-768.	1.2	38
86	Collection of real-world data on nivolumab's effectiveness in renal cell carcinoma: rationale for an observational study. Future Oncology, 2018, 14, 1023-1034.	1.1	1
87	Molecular markers in disease detection and follow-up of patients with non-muscle invasive bladder cancer. Expert Review of Molecular Diagnostics, 2018, 18, 443-455.	1.5	9
88	Expression of tumour progression-associated genes in circulating tumour cells of patients at different stages of prostate cancer. BJU International, 2018, 122, 152-159.	1.3	21
89	Peptide-Based Sandwich Immunoassay for the Quantification of the Membrane Transporter Multidrug Resistance Protein 1. Analytical Chemistry, 2018, 90, 5788-5794.	3.2	6
90	Imaging response assessment of immunotherapy in patients with renal cell and urothelial carcinoma. Current Opinion in Urology, 2018, 28, 35-41.	0.9	12

#	ARTICLE	IF	CITATIONS
91	Targeted vs systematic robot-assisted transperineal magnetic resonance imaging-transrectal ultrasonography fusion prostate biopsy. <i>BJU International</i> , 2018, 121, 791-798.	1.3	22
92	Immunotherapy for kidney cancer. <i>Current Opinion in Urology</i> , 2018, 28, 8-14.	0.9	37
93	Impact of variant microscopic interpretation of the uCyt+ immunocytological urine test for the detection of bladder cancer. <i>Diagnostic Cytopathology</i> , 2018, 46, 111-116.	0.5	5
94	Microvascular and lymphovascular tumour invasion are associated with poor prognosis and metastatic spread in renal cell carcinoma: a validation study in clinical practice. <i>BJU International</i> , 2018, 121, 84-92.	1.3	22
95	Selective Inhibition of the Lactate Transporter MCT4 Reduces Growth of Invasive Bladder Cancer. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 2746-2755.	1.9	53
96	Systemic Alterations of Wnt Inhibitors in Patients with Prostate Cancer and Bone Metastases. <i>Disease Markers</i> , 2018, 2018, 1-5.	0.6	9
97	Performance of Urinary Markers for Detection of Upper Tract Urothelial Carcinoma: Is Upper Tract Urine More Accurate than Urine from the Bladder?. <i>Disease Markers</i> , 2018, 2018, 1-5.	0.6	19
98	Characterization of the breast cancer resistance protein (BCRP/ABCG2) in clear cell renal cell carcinoma. <i>International Journal of Cancer</i> , 2018, 143, 3181-3193.	2.3	40
99	Clinical utility of the S3-score for molecular prediction of outcome in non-metastatic and metastatic clear cell renal cell carcinoma. <i>BMC Medicine</i> , 2018, 16, 108.	2.3	11
100	Transketolase like 1 (TKTL1) expression alterations in prostate cancer tumorigenesis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 472.e21-472.e27.	0.8	13
101	Simultaneous Extraction of RNA and Metabolites from Single Kidney Tissue Specimens for Combined Transcriptomic and Metabolomic Profiling. <i>Journal of Proteome Research</i> , 2018, 17, 3039-3049.	1.8	13
102	Single-use versus reusable ureterorenoscopes for retrograde intrarenal surgery (RIRS): systematic comparative analysis of physical and optical properties in three different devices. <i>World Journal of Urology</i> , 2018, 36, 2059-2063.	1.2	15
103	Abstract CT178: Nivolumab monotherapy in patients with advanced platinum-resistant urothelial carcinoma: Efficacy and safety update and association between biomarkers and overall survival in CheckMate 275. , 2018, , .		10
104	Effectiveness and safety of pazopanib (PAZO) and everolimus (EVE) in a changing treatment (Tx) landscape: Interim results of the non-interventional study PAZOREAL. <i>Journal of Clinical Oncology</i> , 2018, 36, 4584-4584.	0.8	1
105	Abstract 3485: Transcriptomic and metabolomic profiles in renal cell carcinoma (RCC) tumors reflect ontogeny of RCC subtypes. , 2018, , .		0
106	Abstract 5687: Integrative -omics analysis to identify drug targets for ccRCC immunotherapy. , 2018, , .		0
107	Systemic therapy in metastatic renal cell carcinoma. <i>World Journal of Urology</i> , 2017, 35, 179-188.	1.2	117
108	Immunotherapeutic strategies for the treatment of renal cell carcinoma: Where will we go?. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 357-368.	1.1	11

#	ARTICLE	IF	CITATIONS
109	Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. <i>Lancet Oncology</i> , 2017, 18, 312-322.	5.1	1,388
110	Feasibility of accelerated simultaneous multislice diffusion-weighted MRI of the prostate. <i>Journal of Magnetic Resonance Imaging</i> , 2017, 46, 1507-1515.	1.9	19
111	Denosumab treatment in the management of patients with advanced prostate cancer: clinical evidence and experience. <i>Therapeutic Advances in Urology</i> , 2017, 9, 81-88.	0.9	27
112	Immune Checkpoint Inhibition in Metastatic Urothelial Cancer. <i>European Urology</i> , 2017, 72, 477-481.	0.9	36
113	Comment on "Epigenetic activation of the drug transporter OCT2 sensitizes renal cell carcinoma to oxaliplatin". <i>Science Translational Medicine</i> , 2017, 9, .	5.8	4
114	The Value and Evaluability of the PCA3 Urine Assay in Prostate Carcinoma is Independent of the Tumor Localization. <i>Advances in Therapy</i> , 2017, 34, 966-974.	1.3	2
115	Comparison of different concepts for interpretation of chromosomal aberrations in urothelial cells detected by fluorescence in situ hybridization. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 677-685.	1.2	16
116	Comprehensive Metabolomic and Lipidomic Profiling of Human Kidney Tissue: A Platform Comparison. <i>Journal of Proteome Research</i> , 2017, 16, 933-944.	1.8	41
117	Effect of radical prostatectomy on levels of cancer related epitopes in circulating macrophages of patients with clinically localized prostate cancer. <i>Prostate</i> , 2017, 77, 1251-1258.	1.2	5
118	MP64-17 REDUCTION OF POSITIVE SURGICAL MARGINS DUE TO A SIMPLIFIED NEUROS SAFE TECHNIQUE. <i>Journal of Urology</i> , 2017, 197, .	0.2	0
119	The thermoexpandable nitinol stent: a long-term alternative in patients without nephropathy or malignancy. <i>Scandinavian Journal of Urology</i> , 2017, 51, 388-391.	0.6	12
120	Adjuvant Treatment of High-risk Renal Cell Carcinoma: Leaving the Desert?. <i>European Urology</i> , 2017, 71, 695-696.	0.9	14
121	Molecular Signatures of Primary Human Spermatogonial Progenitors and Its Neighboring Peritubular Stromal Compartment. <i>Stem Cells and Development</i> , 2017, 26, 263-273.	1.1	3
122	First report of robot-assisted transperineal fusion versus off-target biopsy in patients undergoing repeat prostate biopsy. <i>World Journal of Urology</i> , 2017, 35, 1023-1029.	1.2	15
123	Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of metastatic renal cell carcinoma (SWITCH-II). <i>Annals of Oncology</i> , 2017, 28, v295.	0.6	17
124	AGS-003 combined with sunitinib for the precision treatment of metastatic renal cell carcinoma. <i>Expert Review of Precision Medicine and Drug Development</i> , 2017, 2, 243-248.	0.4	0
125	Health-related quality of life as a marker of treatment benefit with nivolumab in platinum-refractory patients with metastatic or unresectable urothelial carcinoma from CheckMate 275.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4526-4526.	0.8	3
126	Laparoscopic versus Open Partial Nephrectomy: Comparison of Overall and Subgroup Outcomes. <i>Anticancer Research</i> , 2017, 37, 261-266.	0.5	11

#	ARTICLE	IF	CITATIONS
127	Prediction of Postoperative Risks in Laparoscopic Partial Nephrectomy Using RENAL, Mayo Adhesive Probability and Renal Pelvic Score. <i>Anticancer Research</i> , 2017, 37, 1369-1374.	0.5	16
128	Chronic Periodontitis Does Not Impact Serum Levels of Prostate-specific Antigen. <i>Anticancer Research</i> , 2017, 37, 3163-3167.	0.5	6
129	Abstract 1632: Identification and analysis of EGLN3 as tumor-associated peptide in ccRCC. , 2017, , .		0
130	Abstract 5219: Characterization of the breast cancer resistance protein BCRP in clear cell renal cell carcinoma. , 2017, , .		0
131	Abstract 1843: Intratumoral heterogeneity of renal cancer is related to differences in drug response and development of therapy resistance. , 2017, , .		0
132	Tumour response in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors â€“ assessment of intra-tumour heterogeneity. <i>BMC Medicine</i> , 2016, 14, 201.	2.3	3
133	MP61-03 EVALUATION OF LACTATE TRANSPORTERS AS POTENTIAL THERAPEUTIC TARGET IN UROTHELIAL CARCINOMA. <i>Journal of Urology</i> , 2016, 195, .	0.2	0
134	MP34-09 MEMOKATH 051 â€“ A SAVE ALTERNATIVE FOR TREATMENT OF URETERIC STRICTURES. <i>Journal of Urology</i> , 2016, 195, .	0.2	0
135	Testicular seminoma clinical stage 1: treatment outcome on a routine care level. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 1599-1607.	1.2	48
136	Seminoma Clinical Stage 1 - Patterns of Care in Germany. <i>Urologia Internationalis</i> , 2016, 96, 390-398.	0.6	15
137	IMA901, a multi-peptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1599-1611.	5.1	181
138	Metastasectomy for metastatic renal cell carcinoma in the era of modern systemic treatment: C-reactive protein is an independent predictor of overall survival. <i>International Journal of Urology</i> , 2016, 23, 916-921.	0.5	12
139	Methylomes of renal cell lines and tumors or metastases differ significantly with impact on pharmacogenes. <i>Scientific Reports</i> , 2016, 6, 29930.	1.6	29
140	Liquid biopsy: ready to guide therapy in advanced prostate cancer?. <i>BJU International</i> , 2016, 118, 855-863.	1.3	61
141	Differential expression and clinical relevance of MUC1 in renal cell carcinoma metastasis. <i>World Journal of Urology</i> , 2016, 34, 1635-1641.	1.2	7
142	Re: Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. <i>European Urology</i> , 2016, 69, 538-539.	0.9	3
143	Transcripts of circulating tumor cells detected by a breast cancer-specific platform correlate with clinical stage in bladder cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 1013-1020.	1.2	20
144	Contemporary management of acute kidney trauma. <i>Journal of Acute Disease</i> , 2016, 5, 29-36.	0.0	10

#	ARTICLE	IF	CITATIONS
145	Prostate cancer gene 3 (PCA3) is of additional predictive value in patients with PI-RADS grade III (intermediate) lesions in the MR-guided re-biopsy setting for prostate cancer. <i>World Journal of Urology</i> , 2016, 34, 509-515.	1.2	34
146	MiR-99b-5p expression and response to tyrosine kinase inhibitor treatment in clear cell renal cell carcinoma patients. <i>Oncotarget</i> , 2016, 7, 78433-78447.	0.8	45
147	Abstract 1693: Nicotinamide N-methyltransferase in clear cell renal cell carcinoma primary tumors and metastases. , 2016, , .		0
148	Oncologic Impact of Renal Tissue Adjacent to Renal Cell Carcinoma. <i>Anticancer Research</i> , 2016, 36, 2865-9.	0.5	4
149	17LBA Results from an open-label, randomized, controlled Phase 3 study investigating IMA901 multi-peptide cancer vaccine in patients receiving sunitinib as first-line therapy for advanced/metastatic RCC. <i>European Journal of Cancer</i> , 2015, 51, S718.	1.3	15
150	UCP-3 uncoupling protein confers hypoxia resistance to renal epithelial cells and is upregulated in renal cell carcinoma. <i>Scientific Reports</i> , 2015, 5, 13450.	1.6	21
151	Expression of stage-specific embryonic antigen-4 (SSEA-4) defines spontaneous loss of epithelial phenotype in human solid tumor cells. <i>Glycobiology</i> , 2015, 25, 902-917.	1.3	42
152	Advanced Imaging and Possible Focal Therapy for Prostate Cancer. <i>Current Surgery Reports</i> , 2015, 3, 1.	0.4	1
153	Expression patterns and prognostic role of transketolase-like 1 in muscle-invasive bladder cancer. <i>World Journal of Urology</i> , 2015, 33, 1403-1409.	1.2	9
154	Survival Prediction of Clear Cell Renal Cell Carcinoma Based on Gene Expression Similarity to the Proximal Tubule of the Nephron. <i>European Urology</i> , 2015, 68, 1016-1020.	0.9	55
155	Checkpoint modulation - A new way to direct the immune system against renal cell carcinoma. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 1201-1208.	1.4	11
156	Analysis of Early Morbidity and Functional Outcome of Thulium: Yttrium-Aluminum-Garnet Laser Enucleation for Benign Prostate Enlargement: Patient Age and Prostate Size Determine Adverse Surgical Outcome. <i>Urology</i> , 2015, 85, 182-188.	0.5	33
157	MCT4 surpasses the prognostic relevance of the ancillary protein CD147 in clear cell renal cell carcinoma. <i>Oncotarget</i> , 2015, 6, 30615-30627.	0.8	24
158	mRNA vaccine CV9103 and CV9104 for the treatment of prostate cancer. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 3146-3152.	1.4	74
159	IMA901 for metastatic renal cell carcinoma in the context of new approaches to immunotherapy. <i>Future Oncology</i> , 2014, 10, 937-948.	1.1	10
160	Re: Validation of a Cell-cycle Progression Gene Panel to Improve Risk Stratification in a Contemporary Prostatectomy Cohort. <i>European Urology</i> , 2014, 65, 248.	0.9	0
161	EAU Policy on Live Surgery Events. <i>European Urology</i> , 2014, 66, 87-97.	0.9	50
162	How far is the horizon? From current targets to future drugs in advanced renal cancer. <i>World Journal of Urology</i> , 2014, 32, 69-77.	1.2	0

#	ARTICLE	IF	CITATIONS
163	Targeted therapy in renal cell carcinoma: moving from molecular agents to specific immunotherapy. World Journal of Urology, 2014, 32, 31-38.	1.2	28
164	MP30-05 DETECTION OF TRANSLOCATION TUMOURS ON RENAL CELL CARCINOMA TISSUE MICRO ARRAYS BY FISH. Journal of Urology, 2014, 191, .	0.2	0
165	Predictive chromosomal clusters of synchronous and metachronous brain metastases in clear cell renal cell carcinoma. Cancer Genetics, 2014, 207, 206-213.	0.2	10
166	German second-opinion network for testicular cancer: Sealing the leaky pipe between evidence and clinical practice. Oncology Reports, 2014, 31, 2477-2481.	1.2	28
167	Fournier's Gangrene. , 2014, , 365-368.		0
168	Impact on clinical prognosis using DNA methylation of the SLC16A3 promoter and expression of the human lactate transporter MCT4 in renal cancer.. Journal of Clinical Oncology, 2014, 32, 452-452.	0.8	0
169	Impact of altered Wnt1/β-catenin expression on clinicopathology and prognosis in renal cell carcinoma.. Journal of Clinical Oncology, 2014, 32, 465-465.	0.8	3
170	Abstract 1192: Establishment and characterization of a new patient-derived renal cell carcinoma xenograft panel. , 2014, , .		0
171	Prolonged percutaneous <scp>SNM</scp> testing does not cause infection-related explanation. BJU International, 2013, 111, 485-491.	1.3	21
172	1.2 French stone retrieval baskets further enhance irrigation flow in flexible ureterorenoscopy. Urolithiasis, 2013, 41, 153-157.	1.2	15
173	IMA901: a peptide vaccine in renal cell carcinoma. Expert Opinion on Investigational Drugs, 2013, 22, 1329-1336.	1.9	12
174	Minimally invasive percutaneous nephrolithotomy: an alternative to retrograde intrarenal surgery and shockwave lithotripsy. World Journal of Urology, 2013, 31, 1555-1561.	1.2	48
175	Reply. BJU International, 2013, 111, E20-1.	1.3	2
176	1994 PROSTATIC URETHRAL LIFT (PUL) PROVES EFFICACY IN LUTS TREATMENT OF BPH PATIENTS IN DAILY CLINIC PRACTICE OUTSIDE OF STUDIES. Journal of Urology, 2013, 189, .	0.2	1
177	1550 NANOTECHNOLOGY: 1.2F BASKETS FURTHER ENHANCE IRRIGATION FLOW IN FLEXIBLE URETERORENOSCOPY. Journal of Urology, 2013, 189, .	0.2	0
178	Immunotherapeutic strategies for the treatment of renal cell carcinoma: where are we now?. Expert Review of Anticancer Therapy, 2013, 13, 1399-1408.	1.1	10
179	Minimally Invasive Percutaneous Nephrolithotomy: A Comparative Study of the Management of Small and Large Renal Stones. Urology, 2013, 81, 241-245.	0.5	43
180	Epithelial cell adhesion molecule is an independent prognostic marker in clear cell renal carcinoma. International Journal of Cancer, 2013, 132, 2948-2955.	2.3	25

#	ARTICLE	IF	CITATIONS
181	Myoglobin expression in renal cell carcinoma is regulated by hypoxia. <i>Experimental and Molecular Pathology</i> , 2013, 95, 307-312.	0.9	13
182	303 IMPACT OF ALTERED WNT1/ β 2-CATENIN EXPRESSION ON CLINICOPATHOLOGY AND PROGNOSIS IN RENAL CELL CARCINOMA. <i>Journal of Urology</i> , 2013, 189, .	0.2	0
183	Optimizing treatment of seminoma stage IIA/B step by step. <i>Annals of Oncology</i> , 2013, 24, 2463.	0.6	0
184	Impact of an Altered Wnt1/ β 2-Catenin Expression on Clinicopathology and Prognosis in Clear Cell Renal Cell Carcinoma. <i>International Journal of Molecular Sciences</i> , 2013, 14, 10944-10957.	1.8	55
185	A Rare Case of Synchronous Renal Cell Carcinoma of the Bladder Presenting with Gross Hematuria. <i>Rare Tumors</i> , 2013, 5, 72-74.	0.3	8
186	Treatment of testicular intraepithelial neoplasia (intratubular germ cell neoplasia unspecified) with local radiotherapy or with platinum-based chemotherapy: A survey of the German Testicular Cancer Study Group. <i>Annals of Oncology</i> , 2013, 24, 1332-1337.	0.6	39
187	DNA Methylation of the <i>SLC16A3</i> Promoter Regulates Expression of the Human Lactate Transporter MCT4 in Renal Cancer with Consequences for Clinical Outcome. <i>Clinical Cancer Research</i> , 2013, 19, 5170-5181.	3.2	90
188	Cisplatin Hypersensitivity of Testicular Germ Cell Tumors Is Determined by High Constitutive Noxa Levels Mediated by Oct-4. <i>Cancer Research</i> , 2013, 73, 1460-1469.	0.4	50
189	Use of preoperative C-reactive protein to improve predictive accuracy in clear cell renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, 474-474.	0.8	0
190	CpG island hypermethylation of corticotropin-releasing hormone-binding protein in kidney cancer and association with clinicopathological parameters.. <i>Journal of Clinical Oncology</i> , 2013, 31, 414-414.	0.8	0
191	A vaccine in renal cell carcinoma: are we nearing reality?. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 1503-1505.	1.1	3
192	Biomechanical Proof of Barbed Sutures for the Efficacy of Laparoscopic Pyeloplasty. <i>Journal of Endourology</i> , 2012, 26, 540-544.	1.1	12
193	Human Pregnane X Receptor Genotype of the Donor but Not of the Recipient Is a Risk Factor for Delayed Graft Function After Renal Transplantation. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 91, 905-916.	2.3	17
194	Second-line systemic therapy for the treatment of metastatic renal cell cancer. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 777-785.	1.1	30
195	Kidney-specific cadherin correlates with the ontogenetic origin of renal cell carcinoma subtypes: an indicator of a malignant potential?. <i>World Journal of Urology</i> , 2012, 30, 525-531.	1.2	5
196	V1559 COMBINED THERAPY OF STRESS URINARY INCONTINENCE AND ERECTILE DYSFUNCTION WITH THE IMPLANTATION OF ADVANCE (XP) AND AMS 700 IN A SINGLE PROCEDURE. <i>Journal of Urology</i> , 2012, 187, .	0.2	0
197	Inflammatory prognostic markers in clear cell renal cell carcinoma – preoperative C-reactive protein does not improve predictive accuracy. <i>BJU International</i> , 2012, 110, E771-7.	1.3	17
198	76 Clinical and immunological monitoring of a multi-peptide vaccination trial in patients with stage III renal cell carcinoma. <i>European Urology Supplements</i> , 2012, 11, e76-e76a.	0.1	6

#	ARTICLE	IF	CITATIONS
199	Akt signalling parameters are different in oncocytomas compared to renal cell carcinoma. World Journal of Urology, 2012, 30, 353-359.	1.2	2
200	Modulation of Wnt and Hedgehog Signaling Pathways Is Linked to Retinoic Acid-Induced Amelioration of Chronic Allograft Dysfunction. American Journal of Transplantation, 2012, 12, 55-68.	2.6	11
201	High cytoplasmic expression of p27 ^{Kip1} is associated with a worse cancer-specific survival in clear cell renal cell carcinoma. BJU International, 2012, 109, 1565-1570.	1.3	27
202	Minimally invasive percutaneous nephrolitholapaxy (PCNL) as an effective and safe procedure for large renal stones. BJU International, 2012, 110, E1022-6.	1.3	46
203	Five years into the national second-opinion project of the German Testicular Cancer Group (GCTSG): Impact on guideline implementation and the quality of care for testicular cancer patients.. Journal of Clinical Oncology, 2012, 30, 4530-4530.	0.8	1
204	Association of high cytoplasmic expression of p27 Kip1 on cancer-specific survival in clear cell renal cell carcinoma.. Journal of Clinical Oncology, 2012, 30, 418-418.	0.8	0
205	Abstract 2002: OCT-3/4 expression is associated with high levels of the pro-apoptotic BH3 only protein NOXA in testicular germ cell tumors (TGCTs)., 2012, , .		0
206	1773 IS VEGF TARGETED THERAPY IN RENAL CELL CARCINOMA WITH LATE METASTASES TO THE PANCREAS AND THE THYROID GLAND REASONABLE? " A STUDY OF CHROMOSOMAL IMBALANCES. Journal of Urology, 2011, 185, .	0.2	0
207	246 SPECIFIC CD4+ AND CD8+ T CELLS ACTIVATION BY MULTI-PEPTIDE VACCINATION IN PATIENTS WITH STAGE III RENAL CELL CARCINOMA. Journal of Urology, 2011, 185, .	0.2	0
208	Suppression of Chronic Damage in Renal Allografts by Liver X Receptor (LXR) Activation. American Journal of Pathology, 2011, 179, 92-103.	1.9	21
209	123 ASSESSMENT OF MOLECULAR DIFFERENCES BETWEEN EARLY AND LATELY DEVELOPED RENAL CELL CARCINOMA. Journal of Urology, 2011, 185, .	0.2	0
210	Virtual Bladder Tumor Transurethral Resection: An Objective Evaluation Tool to Overcome Learning Curves with and without Photodynamic Diagnostics. Urologia Internationalis, 2011, 87, 138-142.	0.6	23
211	Underestimated Risk of Bleeding after Male Transobturator Sling Procedure Caused by Early Re-Uptake of Anticoagulation. Urologia Internationalis, 2011, 86, 242-244.	0.6	6
212	Laser fragmentation of foreign bodies in the urinary tract: an in vitro study and clinical application. World Journal of Urology, 2010, 28, 177-180.	1.2	12
213	Tumor-associated macrophages in clear cell renal cell carcinoma express both gastrin-releasing peptide and its receptor: a possible modulatory role of immune effectors cells. World Journal of Urology, 2010, 28, 335-341.	1.2	11
214	Viral macrophage inflammatory protein-II improves acute rejection in allogeneic rat kidney transplants. World Journal of Urology, 2010, 28, 537-542.	1.2	4
215	Incidental prostate cancer at radical cystoprostatectomy: implications for apex-sparing surgery. BJU International, 2010, 105, 468-471.	1.3	39
216	630 TFE3-TRANSLOCATION TUMOURS ARE MORE FREQUENT IN YOUNG ADULTS THAN IN OLD RENAL CELL CARCINOMA PATIENTS. Journal of Urology, 2010, 183, .	0.2	0

#	ARTICLE	IF	CITATIONS
217	1019 DOES BIOFILM RISK THE TREATMENT SUCCESS ATTAINED FROM THE TWO STEP IMPLANTATION OF A CHRONIC SACRAL NEUROMODULATOR?. Journal of Urology, 2010, 183, .	0.2	1
218	A novel CXCL8 protein-based antagonist in acute experimental renal allograft damage. Molecular Immunology, 2010, 47, 1047-1057.	1.0	30
219	Peroxisome Proliferator-Activated Receptor (PPAR) ^Î 3 Can Inhibit Chronic Renal Allograft Damage. American Journal of Pathology, 2010, 176, 2150-2162.	1.9	34
220	Immunologic mechanisms in RCC and allogeneic renal transplant rejection. Nature Reviews Urology, 2010, 7, 339-347.	1.9	13
221	Adjuvant multi-peptide vaccination in high-risk renal cell carcinoma.. Journal of Clinical Oncology, 2010, 28, e15051-e15051.	0.8	1
222	Activation of mTOR in renal cell carcinoma is due to increased phosphorylation rather than protein overexpression. Oncology Reports, 2010, 23, 159-63.	1.2	26
223	Wnt Pathway Regulation in Chronic Renal Allograft Damage. American Journal of Transplantation, 2009, 9, 2223-2239.	2.6	80
224	STAT-1 decoy oligodeoxynucleotide inhibition of acute rejection in mouse heart transplants. Basic Research in Cardiology, 2009, 104, 719-729.	2.5	21
225	Impact of preoperative haemoglobin concentrations on the efficiency of KTP-laser vaporization of the prostate. World Journal of Urology, 2009, 27, 405-409.	1.2	0
226	Economic aspects of bladder cancer: what are the benefits and costs?. World Journal of Urology, 2009, 27, 295-300.	1.2	378
227	Novel multi-peptide vaccination in Hla ^{A2+} hormone sensitive patients with biochemical relapse of prostate cancer. Prostate, 2009, 69, 917-927.	1.2	97
228	Perinephric and renal sinus fat infiltration in pT3a renal cell carcinoma: possible prognostic differences. BJU International, 2009, 103, 1349-1354.	1.3	63
229	<i>En bloc</i> stapler ligation of the renal vascular pedicle during laparoscopic nephrectomy. BJU International, 2008, 101, 878-882.	1.3	22
230	The influence of body mass index on the long-term survival of patients with renal cell carcinoma after tumour nephrectomy. BJU International, 2008, 101, 1243-1246.	1.3	51
231	High nuclear Livin expression is a favourable prognostic indicator in renal cell carcinoma. BJU International, 2008, 102, 1700-1706.	1.3	15
232	Re: Efficacy of Sunitinib and Sorafenib in Metastatic Papillary and Chromophobe Renal Cell Carcinoma. European Urology, 2008, 54, 1200-1201.	0.9	0
233	Prognostic Stratification of Localized Renal Cell Carcinoma by Tumor Size. Journal of Urology, 2008, 180, 62-67.	0.2	34
234	MULTIVARIATE ANALYSIS OF PATIENTS TREATED WITH RADICAL CYSTECTOMY EVALUATING NEWLY PROPOSED PROGNOSTIC FACTORS FOR BLADDER CANCER SPECIFIC SURVIVAL. Journal of Urology, 2008, 179, 550-551.	0.2	0

#	ARTICLE	IF	CITATIONS
235	Evaluation and management of a patient with a bladder mass of uncertain etiology. <i>Nature Reviews Urology</i> , 2008, 5, 509-514.	1.4	1
236	Expression of inhibitor of apoptosis protein Livin in renal cell carcinoma and non-tumorous adult kidney. <i>British Journal of Cancer</i> , 2007, 97, 1271-1276.	2.9	33
237	Anti-Inflammatory Effects of α v Integrin Antagonism in Acute Kidney Allograft Rejection. <i>American Journal of Pathology</i> , 2007, 171, 1127-1139.	1.9	17
238	1306: Tumor-Size Breakpoint for Prognostic Stratification of Localized Renal Cell Carcinoma (RCC). <i>Journal of Urology</i> , 2007, 177, 430-430.	0.2	68
239	STAT-1 decoy oligonucleotide improves microcirculation and reduces acute rejection in allogeneic rat small bowel transplants. <i>Gene Therapy</i> , 2007, 14, 883-890.	2.3	17
240	Repeated botulinum-A toxin injections in the treatment of myelodysplastic children and patients with spinal cord injuries with neurogenic bladder dysfunction. <i>BJU International</i> , 2007, 100, 639-645.	1.3	92
241	Beneficial Effects of CCR1 Blockade on the Progression of Chronic Renal Allograft Damage. <i>American Journal of Transplantation</i> , 2007, 7, 527-537.	2.6	55
242	822: Botulinum Toxin Type a (Dysport®) for the Treatment of Children with Neurogenic Detrusor Overactivity Due to Myelodysplasia (MMC). <i>Journal of Urology</i> , 2007, 177, 274-274.	0.2	0
243	Physical and Biological Characterization of Superparamagnetic Iron Oxide- and Ultrasmall Superparamagnetic Iron Oxide-Labeled Cells. <i>Investigative Radiology</i> , 2005, 40, 504-513.	3.5	84
244	ROLE OF XANTHINE OXIDOREDUCTASE IN EXPERIMENTAL ACUTE RENAL-ALLOGRAFT REJECTION. <i>Transplantation</i> , 2004, 77, 1683-1692.	0.5	26
245	Einmalige Vorbehandlung der SpendergefäÙe mit einem Decoy-Oligonukleotid gegen STAT-1 verbessert die mukosale Perfusion und reduziert die CSA-Dosis im allogenen DÄ¼ndarmtransplantationsmodell der Ratte. <i>Langenbecks Archiv F¼r Chirurgie Supplement</i> , 2004, , 335-336.	0.0	0
246	Met-RANTES Inhibition of Mucosal Perfusion Failure in Acute Intestinal Transplant Rejection – Role of Endothelial Cell-Leukocyte Interaction. <i>Journal of Vascular Research</i> , 2002, 39, 51-58.	0.6	22
247	Met-RANTES improves acute-rejection-induced microvascular injury in rat small bowel transplantation. <i>Transplantation Proceedings</i> , 2002, 34, 1049.	0.3	12
248	Met-RANTES verbessert die mikrokapillÄ¼re Perfusion wÄ¼hrend der akuten AbstoÙung am DÄ¼ndarmtransplantat der Ratte. <i>Langenbecks Archiv F¼r Chirurgie Supplement</i> , 2002, , 271-273.	0.0	0
249	In vivo changes in acute rejection of rat small bowel allografts. <i>Transplantation Proceedings</i> , 2000, 32, 1247-1248.	0.3	7
250	A Molecularly Characterized Preclinical Platform of Subcutaneous Renal Cell Carcinoma (RCC) Patient-Derived Xenograft Models to Evaluate Novel Treatment Strategies. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2